Treatment News : FDA Accepts New Applications for Cobicistat and Elvitegravir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 24, 2014

FDA Accepts New Applications for Cobicistat and Elvitegravir

As of April 21, the U.S. Food and Drug Administration (FDA) has accepted Gilead Sciences’ resubmitted applications for the approval of cobicistat and elvitegravir to treat HIV. The company seeks the FDA’s imprimatur to market cobicistat as a pharmacoenhancing, or boosting, agent that raises the blood levels of the protease inhibitors Reyataz (atazanavir) and Prezista (darunavir) as well as the integrase inhibitor elvitegravir, allowing them to be dosed just once daily. In addition, Gilead seeks approval for elvitegravir’s use in treatment-experienced adults.

The company had submitted new drug applications for the antiretrovirals in mid-2012, but the FDA responded nearly a year later that it could not sign off on them because of shortcomings in Gilead’s provided documentation supporting the drugs.  Gilead states that it has since worked with the FDA to address these problems.

The FDA’s decisions for the applications are expected on October 3 and 4.

Janssen, which developed Prezista, filed an applicationwith the FDA on April 1 for approval of a once-daily fixed-dose combination tablet of that drug and cobicistat. And on April 22 Bristol-Myers Squibb filed for approval of a fixed-dose tablet of the company’s Reyataz (atazanavir) and cobicistat.

To read the Gilead press release, click here.

Search: U.S. Food and Drug Administration, FDA, cobicistat, elvitegravir, boosting agent, Prezista, darunavir, Reyataz, atazanavir, Gilead Sciences.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    mtaj0818
    Washington
    DC


    youngbloodlatino
    Columbia
    Maryland


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.